Young adults and acceptance of the human papillomavirus vaccine

This publication has 21 references indexed in Scilit:

• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• Is the public enough aware to accept a vaccination program against human papillomavirus?
  Vaccine, 2005
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
  The Lancet Oncology, 2005
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
  The Lancet, 2004
• Adults' Knowledge and Behaviors Related to Human Papillomavirus Infection
  The Journal of the American Board of Family Medicine, 2004
• Awareness of human papillomavirus among women attending a well woman clinic
  Sexually Transmitted Infections, 2003
• Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of Causality
  JNCI Monographs, 2003
• A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
  New England Journal of Medicine, 2002
• Knowledge about human papillomavirus among adolescents
  Obstetrics & Gynecology, 2000
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
  The Journal of Pathology, 1999